Rivaroxaban and Hemopericardium – Is There an Association?

Case Report

Austin Cardio & Cardiovasc Case Rep. 2017; 2(1): 1015.

Rivaroxaban and Hemopericardium – Is There an Association?

Gowani SA1, Omar S¹, Elmahdy HM², Kherada N¹, Sekhon A¹, Conde C¹ and Santana O¹*

¹The Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, Florida, USA

²Department of Internal Medicine at Mount Sinai Medical Center, Miami Beach, Florida, USA

*Corresponding author: Orlando Santana, Echocardiography Laboratory, Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, Florida, USA

Received: February 20, 2017; Accepted: March 14, 2017; Published: March 20, 2017

Abstract

Newer oral anticoagulants are being used more frequently in patients with non-valvular atrial fibrillation. Rivaroxaban is one of the new oral anticoagulants which acts as a direct factor Xa inhibitor. The overall bleeding risk from using rivaroxaban in patients with atrial fibrillation is 14.9%/year, and the risk of any major bleed is 3.6%/year. We present a case of a 68 years old gentleman patient who underwent recent atrial lead re-positioning and developed hemopericardium in the setting of pericarditis.

Keywords: Atrial fibrillation; Rivaroxaban; Hemopericardium; Direct Xa inhibitors

Introduction

Atrial fibrillation has been described as a growing epidemic that will affect a quarter of adults older than 40 years of age [1]. Rivaroxaban is one of the newer oral anticoagulant approved for use in the patients with non-valvular atrial fibrillation [2]. It has also been approved for other indications (Table 1). Its use has increased owing to its rapid onset of action, predictable therapeutic level, ease of standard dose administration without the need for monitoring laboratory tests and limited interaction with other drugs [3]; however, as with all anticoagulants, there is a risk of bleeding complications.